{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:17:29Z","timestamp":1793654249281,"version":"4.5.1"},"reference-count":142,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Molecular bases of disease dissemination in lymphoid malignancies","award":["5 \u00d7 1000 No. 21198"],"award-info":[{"award-number":["5 \u00d7 1000 No. 21198"]}]},{"name":"Molecular bases of disease dissemination in lymphoid malignancies","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}]},{"DOI":"10.13039\/501100003196","name":"AGING Project\u2013Department of Excellence\u2013DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","doi-asserted-by":"publisher","award":["5 \u00d7 1000 No. 21198"],"award-info":[{"award-number":["5 \u00d7 1000 No. 21198"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"AGING Project\u2013Department of Excellence\u2013DIMET, Universit\u00e0 del Piemonte Orientale, Novara, Italy","doi-asserted-by":"publisher","award":["PNRR-MAD-2022-12375673"],"award-info":[{"award-number":["PNRR-MAD-2022-12375673"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Liquid biopsy through the analysis of circulating tumor DNA (ctDNA) is emerging as a powerful and non-invasive tool complementing tissue biopsy in lymphoma management. Whilst tissue biopsy remains the diagnostic gold standard, it fails to detect the molecular heterogeneity of the tumor\u2019s multiple compartments and poses challenges for sequential disease monitoring. In diffuse large-B-cell lymphoma (DLBCL), ctDNA facilitates non-invasive genotyping by identifying hallmark mutations (e.g., MYD88, CD79B, EZH2), enabling molecular cluster classification. Dynamic changes in ctDNA levels during DLBCL treatment correlate strongly with progression-free survival and overall survival, underscoring its value as a predictive and prognostic biomarker. In Hodgkin\u2019s lymphoma, characterized by a scarcity of malignant cells in tissue biopsies, ctDNA provides reliable molecular insights into tumor biology, response to therapy, and relapse risk. In primary central nervous system lymphoma, the detection of MYD88 L265P in ctDNA offers a highly sensitive, specific, and minimally invasive diagnostic option. Likewise, in aggressive T-cell lymphomas, ctDNA supports molecular profiling, aligns with tumor burden, and shows high concordance with tissue-based results. Ongoing and future clinical trials will be critical for validating and standardizing ctDNA applications, ultimately integrating liquid biopsy into routine clinical practice and enabling more personalized and dynamic lymphoma care.<\/jats:p>","DOI":"10.3390\/ijms26104869","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:54:26Z","timestamp":1747655666000},"page":"4869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-3845","authenticated-orcid":false,"given":"Mohammad","family":"Almasri","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9307-1965","authenticated-orcid":false,"given":"Nawar","family":"Maher","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"},{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria di Alessandria, 56121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-1917","authenticated-orcid":false,"given":"Bashar","family":"Al Deeban","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1551-8801","authenticated-orcid":false,"given":"Ndeye Marie","family":"Diop","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Moia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carit\u00e0, 28100 Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2016.07.012","article-title":"Lymphoma","volume":"43","author":"Mugnaini","year":"2016","journal-title":"Prim. Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102106","DOI":"10.1016\/j.ctrv.2020.102106","article-title":"Liquid biopsy in lymphoma: Molecular methods and clinical applications","volume":"91","author":"Cirillo","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chan, H.T., Chin, Y.M., and Low, S.K. (2022). Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges. Cancers, 14.","DOI":"10.3390\/cancers14133275"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Talotta, D., Almasri, M., Cosentino, C., Gaidano, G., and Moia, R. (2023). Liquid biopsy in hematological malignancies: Current and future applications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1164517"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: Current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Matuszczak, M., Schalken, J.A., and Salagierski, M. (2021). Prostate Cancer Liquid Biopsy Biomarkers\u2019 Clinical Utility in Diagnosis and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13133373"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cimb44060184","article-title":"Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy","volume":"44","author":"Liu","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.17718","article-title":"Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma","volume":"195","author":"Moia","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Savino, F.D., Rigali, F., Giustini, V., D\u2019Aliberti, D., Spinelli, S., Piazza, R., Sacco, A., and Roccaro, A.M. (2022). Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders. Cancers, 14.","DOI":"10.3390\/cancers14215378"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1080\/10428194.2024.2389210","article-title":"Prospects for liquid biopsy approaches in lymphomas","volume":"65","author":"Jamal","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA apoptosis and active DNA release","volume":"313","author":"Stroun","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of circulating cell-free DNA for biomedical applications: Critical appraisal of the literature","volume":"4","author":"Khier","year":"2018","journal-title":"Future Sci. OA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(97)02174-0","article-title":"Presence of fetal DNA in maternal plasma and serum","volume":"350","author":"Lo","year":"1997","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E8159","DOI":"10.1073\/pnas.1615800113","article-title":"Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends","volume":"113","author":"Chan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"16266","DOI":"10.1073\/pnas.0808319105","article-title":"Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood","volume":"105","author":"Fan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101237","DOI":"10.1016\/j.blre.2024.101237","article-title":"Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future","volume":"68","author":"Li","year":"2024","journal-title":"Blood Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ogawa, M., Yokoyama, K., Imoto, S., and Tojo, A. (2021). Role of Circulating Tumor DNA in Hematological Malignancy. Cancers, 13.","DOI":"10.3390\/cancers13092078"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhu, D., Wang, H., Wu, W., Geng, S., Zhong, G., Li, Y., Guo, H., Long, G., Ren, Q., and Luan, Y. (2023). Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis. BMC Biol., 21.","DOI":"10.1186\/s12915-023-01752-6"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-050520-044652","article-title":"Molecular Monitoring of Lymphomas","volume":"18","author":"Alig","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","article-title":"Circulating tumour DNA\u2014Looking beyond the blood","volume":"19","author":"Tivey","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1515\/cclm-2014-1161","article-title":"Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): The SPIDIA-DNAplas External Quality Assessment experience","volume":"53","author":"Malentacchi","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/cclm-2019-0896","article-title":"Plasma vs. serum in circulating tumor DNA measurement: Characterization by DNA fragment sizing and digital droplet polymerase chain reaction","volume":"58","author":"Lee","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.clinbiochem.2015.07.097","article-title":"Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA","volume":"48","author":"Toro","year":"2015","journal-title":"Clin. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative analysis of circulating tumor DNA stability In K(3)EDTA, Streck, and CellSave blood collection tubes","volume":"49","author":"Kang","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-041316-085721","article-title":"Circulating Tumor DNA: Measurement and Clinical Utility","volume":"69","author":"Donaldson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1196\/annals.1368.042","article-title":"The importance of careful blood processing in isolation of cell-free DNA","volume":"1075","author":"Page","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Johansson, G., Andersson, D., Filges, S., Li, J., Muth, A., Godfrey, T.E., and St\u00e5hlberg, A. (2019). Considerations and quality controls when analyzing cell-free tumor DNA. Biomol. Detect. Quantif., 17.","DOI":"10.1016\/j.bdq.2018.12.003"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating Tumor DNA in Lymphoma: Principles and Future Directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: A cancer diagnostic perspective","volume":"18","author":"Postel","year":"2018","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: Current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.csbj.2020.08.011","article-title":"UMI-Gen: A UMI-based read simulator for variant calling evaluation in paired-end sequencing NGS libraries","volume":"18","author":"Sater","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/bloodadvances.2024014136","article-title":"Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels","volume":"9","author":"Moia","year":"2025","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: A prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8765","DOI":"10.18632\/oncotarget.14448","article-title":"The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma","volume":"8","author":"Sarkozy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Poza","year":"2023","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax","volume":"28","author":"Weiss","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Li, Q., Zhang, W., Li, J., Xiong, J., Liu, J., Chen, T., Wen, Q., Zeng, Y., Gao, L., and Gao, L. (2020). Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK\/T-cell lymphoma. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00205-4"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18824","article-title":"Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma","volume":"202","author":"Wei","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study","volume":"27","author":"Nadeu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: Technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2023-180007","article-title":"End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET\/CT Scan Versus Ultrasensitive Circulating Tumor DNA","volume":"142","author":"Roschewski","year":"2023","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e008450","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.21037\/tcr-23-1396","article-title":"A STEP ahead for CAR-T cell therapy of large B cell lymphoma: Understanding the molecular determinants of resistance","volume":"12","author":"Mouhssine","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2019-131267","article-title":"Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA","volume":"134","author":"Alizadeh","year":"2019","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428194.2015.1037758","article-title":"Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation","volume":"57","author":"Scherer","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","author":"Oki","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"key":"ref_79","first-page":"746","article-title":"Evaluation of apoptosis in classical Hodgkin\u2019s lymphoma comparing different methods","volume":"17","author":"Georgiadi","year":"2012","journal-title":"J. Balk. Union Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","article-title":"The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion","volume":"157","author":"Hu","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","article-title":"Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma","volume":"91","author":"Jardin","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41379-019-0428-0","article-title":"Diagnostic utility of STAT6(YE361) expression in classical Hodgkin lymphoma and related entities","volume":"33","author":"Huh","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","article-title":"The landscape of copy number variations in classical Hodgkin lymphoma: A joint KU Leuven and LYSA study on cell-free DNA","volume":"5","author":"Buedts","year":"2021","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"ref_87","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematologica"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_92","first-page":"E148","article-title":"Morbidity of stereotactic biopsy for intracranial lesions","volume":"56","author":"Nishihara","year":"2011","journal-title":"Kobe J. Med. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hickmann, A.K., Frick, M., Hadaschik, D., Battke, F., Bittl, M., Ganslandt, O., Biskup, S., and D\u00f6cker, D. (2019). Molecular tumor analysis and liquid biopsy: A feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5394-x"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/neuonc\/noae032","article-title":"Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review","volume":"26","author":"Nayak","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Godlewska","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bjh.13293","article-title":"Absence of CXCR4 mutations but high incidence of double mutant in CD79A\/B and MYD88 in primary central nervous system lymphoma","volume":"170","author":"Poulain","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: Results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00308","article-title":"High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas","volume":"3","author":"Watanabe","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jmoldx.2020.07.002","article-title":"Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy","volume":"22","author":"Brunn","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood.2020010137","article-title":"A rapid genotyping panel for detection of primary central nervous system lymphoma","volume":"138","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1111\/cas.15133","article-title":"Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma","volume":"112","author":"Yamagishi","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: A valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/IAE.0000000000002319","article-title":"MYD88 L265P Mutation Detection in the Aqueous Humor of Patients with Vitreoretinal Lymphoma","volume":"39","author":"Miserocchi","year":"2019","journal-title":"Retina"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"48157","DOI":"10.18632\/oncotarget.18325","article-title":"Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma","volume":"8","author":"Fontanilles","year":"2017","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zorofchian, S., Lu, G., Zhu, J.J., Duose, D.Y., Windham, J., Esquenazi, Y., and Ballester, L.Y. (2018). Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00382"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41375-024-02279-7","article-title":"Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma","volume":"38","author":"Liang","year":"2024","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: Distinct prognostic value in follicular lymphoma","volume":"2","author":"Dupuis","year":"2018","journal-title":"Blood Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study","volume":"29","author":"Pedrosa","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Galimberti, S., Genuardi, E., Mazziotta, F., Iovino, L., Morabito, F., Grassi, S., Ciabatti, E., Guerrini, F., and Petrini, M. (2019). The Minimal Residual Disease in Non-Hodgkin\u2019s Lymphomas: From the Laboratory to the Clinical Practice. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00528"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Maher, N., Mouhssine, S., Matti, B.F., Alwan, A.F., and Gaidano, G. (2025). Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies. Cancers, 17.","DOI":"10.3390\/cancers17050907"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00428-022-03460-y","article-title":"Chronic lymphocytic leukaemia\/small lymphocytic lymphoma and mantle cell lymphoma: From early lesions to transformation","volume":"482","author":"Sander","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41375-024-02499-x","article-title":"Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement","volume":"39","author":"Nabki","year":"2025","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/10428194.2024.2449214","article-title":"Prognostic factors in chronic lymphocytic leukaemia\u2014The old, the new and the future","volume":"66","author":"McKeague","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/hematolrep16020027","article-title":"Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia","volume":"16","author":"Mouhssine","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","article-title":"Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?","volume":"3","author":"Eichhorst","year":"2019","journal-title":"Hemasphere"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","article-title":"Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months","volume":"4","author":"Lew","year":"2020","journal-title":"Blood Adv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron","year":"2007","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Condoluci, A., Romano, I., Dietrich, D., Pini, K., Stussi, G., M\u00fcller, G., Cantoni, N., Cathomas, R., Mey, U.J.M., and Widmer, A.A. (2025). Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia\u2014SAKK 34\/17. Blood, in press.","DOI":"10.1182\/blood.2024026879"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ajh.27165","article-title":"Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management","volume":"99","author":"Ong","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-024-01947-7","article-title":"Liquid biopsy in T-cell lymphoma: Biomarker detection techniques and clinical application","volume":"23","author":"Huang","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7150\/jca.27615","article-title":"Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA","volume":"10","author":"Sun","year":"2019","journal-title":"J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2020001637","article-title":"Liquid biopsy in extranodal NK\/T-cell lymphoma: A prospective analysis of cell-free DNA genotyping and monitoring","volume":"5","author":"Qi","year":"2021","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ejh.13736","article-title":"Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma","volume":"108","author":"Fu","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4143\/crt.2022.017","article-title":"Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_139","first-page":"4198","article-title":"Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1007\/s00330-020-06732-w","article-title":"Comparison of whole-body MRI with diffusion-weighted imaging and PET\/CT in lymphoma staging","volume":"30","author":"Kharuzhyk","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1182\/blood-2024-207234","article-title":"A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna","volume":"144","author":"Salehi","year":"2024","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2024-198355","article-title":"Preliminary Data on the Efficacy and Safety of Orelabrutinib Combined with Rituximab and Methotrexate (ORM Regimen) As First-Line Treatment for Primary Central Nervous System Lymphoma, and the Exploration of Cerebrospinal Fluid Ctdna Dynamic Monitoring","volume":"144","author":"Sheng","year":"2024","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:18Z","timestamp":1760031318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":142,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26104869"],"URL":"https:\/\/doi.org\/10.3390\/ijms26104869","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}